Delivra Health Brands (DHB) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
26 Dec, 2025Executive summary
Achieved a 34% year-over-year increase in Q2 net sales, driven by strong Dream Water performance in the U.S. and Canada, and expanded marketing investments, though partially offset by lower LivRelief sales in Canada.
Completed a 10-to-1 stock consolidation to improve trading dynamics and broaden investor accessibility.
Focused on operational excellence, innovation, and expanding distribution across North America and internationally.
Increased marketing and promotional investments aimed at expanding brand awareness and customer base.
Management remains confident in achieving commercial and financial objectives for the fiscal year.
Financial highlights
Q2 Fiscal 2025 net sales reached CAD 2.8 million ($2,754K), up from CAD 2.1 million ($2,050K) in the same quarter last year; six-month net sales were CAD 5.9 million ($5,917K), up 3% year-over-year.
Q2 2025 gross profit was $1,294K (margin 47%), up from $1,104K (margin 54%) in Q2 2024; six-month gross profit was $2,891K (margin 49%), down from $3,027K (margin 53%).
Q2 net loss was CAD 194,000, compared to a net loss of CAD 84,000 in the prior quarter, mainly due to increased marketing spend; Q2 2025 net loss: $(812)K (EPS: $(0.03)); six-month net loss: $(1,288)K (EPS: $(0.04)).
Adjusted EBITDA for the first half was a loss of CAD 176,000, following positive adjusted EBITDA in 2023 and 2024; Q2 2025 Adjusted EBITDA: $(194)K, down from $(84)K in Q2 2024.
Q2 2025 expenses (excluding non-cash): $1,544K, up 22% year-over-year; six-month expenses: $3,149K, up 22%.
Outlook and guidance
Management remains positive about future growth, with plans to balance marketing investments and operational efficiency.
On track to achieve full-year commercial and financial objectives, supported by ongoing marketing and product initiatives.
Additional SKUs and innovation programs are planned for the second half of the year.
Focus on long-term value creation and scalability, despite market and consumer behavior challenges.
Latest events from Delivra Health Brands
- E-commerce growth offset retail declines, with management prioritizing channel stabilization and U.S. expansion.DHB
Q2 20261 Mar 2026 - Record revenue, margin expansion, and positive EBITDA highlight a strong FY2024 and future growth.DHB
Q4 202419 Jan 2026 - Turnaround delivers strong margins, growth, and global expansion in wellness products.DHB
Investor Update14 Nov 2025 - 8% revenue growth and double-digit brand gains drive outlook, despite EBITDA decline.DHB
Q4 20256 Oct 2025 - Clinically proven wellness brands achieved 26% revenue growth and positive EBITDA in 2024.DHB
Corporate Presentation11 Jul 2025 - Q3 2025 delivered revenue growth and positive adjusted EBITDA amid expanded product offerings.DHB
Q3 202510 Jul 2025